Fairvalue-Calculator Fairvalue-Calculator
EN DE

PepGen Inc (PEPG) Fair Value & Analysis

Healthcare · US · Market cap $133M

Price$1.77
Fair Value$1.80
Upside+1.7%
Quality95/100
Evidence: Low Range $1.19 – $2.25

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

PepGen Inc (PEPG) currently trades at $1.77, while our model-based Fair Value estimate is $1.80 — implying the stock looks roughly 1.7% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is PepGen Inc (PEPG) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $1.80 versus a price of $1.77 — about +2% (undervalued). Model-based estimate, not financial advice.
What is the fair value of PEPG?
Our 21-model fair value for PepGen Inc is $1.80 (as of Jun 25, 2026), built from audited fundamentals. The current price is $1.77.
What is the quality score of PEPG?
PepGen Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.